25 XP   0   0   10

Calliditas Therapeutics
Buy, Hold or Sell?

Let's analyse Calliditas together

PenkeI guess you are interested in Calliditas Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Calliditas Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Calliditas Therapeutics

I send you an email if I find something interesting about Calliditas Therapeutics.

Quick analysis of Calliditas (30 sec.)










What can you expect buying and holding a share of Calliditas? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr6.24
Expected worth in 1 year
kr-1.80
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
kr-8.04
Return On Investment
-7.1%

For what price can you sell your share?

Current Price per Share
kr113.40
Expected price per share
kr105.80 - kr141.90
How sure are you?
50%

1. Valuation of Calliditas (5 min.)




Live pricePrice per Share (EOD)

kr113.40

Intrinsic Value Per Share

kr66.41 - kr83.38

Total Value Per Share

kr72.65 - kr89.62

2. Growth of Calliditas (5 min.)




Is Calliditas growing?

Current yearPrevious yearGrowGrow %
How rich?$31.4m$72.4m-$30.6m-73.2%

How much money is Calliditas making?

Current yearPrevious yearGrowGrow %
Making money-$10.9m-$9.6m-$1.2m-11.6%
Net Profit Margin-48.3%-180.3%--

How much money comes from the company's main activities?

3. Financial Health of Calliditas (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#168 / 1031

Most Revenue
#184 / 1031

Most Profit
#606 / 1031

Most Efficient
#553 / 1031

What can you expect buying and holding a share of Calliditas? (5 min.)

Welcome investor! Calliditas's management wants to use your money to grow the business. In return you get a share of Calliditas.

What can you expect buying and holding a share of Calliditas?

First you should know what it really means to hold a share of Calliditas. And how you can make/lose money.

Speculation

The Price per Share of Calliditas is kr113.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Calliditas.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Calliditas, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr6.24. Based on the TTM, the Book Value Change Per Share is kr-2.01 per quarter. Based on the YOY, the Book Value Change Per Share is kr-1.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Calliditas.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.030.0%-0.20-0.2%-0.18-0.2%-0.16-0.1%-0.16-0.1%
Usd Book Value Change Per Share-0.030.0%-0.19-0.2%-0.11-0.1%-0.020.0%0.030.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.030.0%-0.19-0.2%-0.11-0.1%-0.020.0%0.030.0%
Usd Price Per Share11.95-10.26-8.44-9.10-8.86-
Price to Earnings Ratio-92.85--30.56--118.50--31.69--30.81-
Price-to-Total Gains Ratio-386.96--128.54-248.43--2.39--2.09-
Price to Book Ratio20.38-13.96-6.29-7.13-6.98-
Price-to-Total Gains Ratio-386.96--128.54-248.43--2.39--2.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.6596
Number of shares93
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.19-0.02
Usd Total Gains Per Share-0.19-0.02
Gains per Quarter (93 shares)-17.57-2.31
Gains per Year (93 shares)-70.27-9.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-70-800-9-19
20-141-1500-18-28
30-211-2200-28-37
40-281-2900-37-46
50-351-3600-46-55
60-422-4300-55-64
70-492-5000-65-73
80-562-5700-74-82
90-632-6400-83-91
100-703-7100-92-100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%2.019.00.09.5%2.019.00.09.5%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%7.014.00.033.3%7.014.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%7.014.00.033.3%7.014.00.033.3%

Fundamentals of Calliditas

About Calliditas Therapeutics

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2024-03-07 22:45:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Calliditas Therapeutics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Calliditas earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Calliditas to the Biotechnology industry mean.
  • A Net Profit Margin of -4.1% means that kr-0.04 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Calliditas Therapeutics:

  • The MRQ is -4.1%. The company is making a loss. -1
  • The TTM is -48.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4.1%TTM-48.3%+44.3%
TTM-48.3%YOY-180.3%+131.9%
TTM-48.3%5Y-2,882.2%+2,833.8%
5Y-2,882.2%10Y-8,144.7%+5,262.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.1%-159.2%+155.1%
TTM-48.3%-202.3%+154.0%
YOY-180.3%-263.0%+82.7%
5Y-2,882.2%-452.4%-2,429.8%
10Y-8,144.7%-589.0%-7,555.7%
1.1.2. Return on Assets

Shows how efficient Calliditas is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Calliditas to the Biotechnology industry mean.
  • -1.0% Return on Assets means that Calliditas generated kr-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Calliditas Therapeutics:

  • The MRQ is -1.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.0%TTM-6.8%+5.8%
TTM-6.8%YOY-7.3%+0.5%
TTM-6.8%5Y-6.5%-0.3%
5Y-6.5%10Y-6.5%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.0%-12.5%+11.5%
TTM-6.8%-12.2%+5.4%
YOY-7.3%-11.2%+3.9%
5Y-6.5%-13.3%+6.8%
10Y-6.5%-14.6%+8.1%
1.1.3. Return on Equity

Shows how efficient Calliditas is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Calliditas to the Biotechnology industry mean.
  • -5.5% Return on Equity means Calliditas generated kr-0.05 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Calliditas Therapeutics:

  • The MRQ is -5.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-25.8%+20.3%
TTM-25.8%YOY-13.0%-12.8%
TTM-25.8%5Y-12.3%-13.5%
5Y-12.3%10Y-12.0%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%-16.0%+10.5%
TTM-25.8%-15.8%-10.0%
YOY-13.0%-13.9%+0.9%
5Y-12.3%-18.2%+5.9%
10Y-12.0%-19.1%+7.1%

1.2. Operating Efficiency of Calliditas Therapeutics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Calliditas is operating .

  • Measures how much profit Calliditas makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Calliditas to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Calliditas Therapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-43.8%+43.8%
TTM-43.8%YOY-190.9%+147.1%
TTM-43.8%5Y-2,473.6%+2,429.8%
5Y-2,473.6%10Y-7,824.0%+5,350.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-43.8%-208.5%+164.7%
YOY-190.9%-280.2%+89.3%
5Y-2,473.6%-459.9%-2,013.7%
10Y-7,824.0%-596.9%-7,227.1%
1.2.2. Operating Ratio

Measures how efficient Calliditas is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.93 means that the operating costs are kr0.93 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Calliditas Therapeutics:

  • The MRQ is 0.935. The company is less efficient in keeping operating costs low.
  • The TTM is 1.429. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.935TTM1.429-0.495
TTM1.429YOY2.882-1.453
TTM1.4295Y26.117-24.688
5Y26.11710Y79.555-53.438
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9352.817-1.882
TTM1.4293.181-1.752
YOY2.8823.609-0.727
5Y26.1175.554+20.563
10Y79.5557.396+72.159

1.3. Liquidity of Calliditas Therapeutics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Calliditas is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.13 means the company has kr3.13 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Calliditas Therapeutics:

  • The MRQ is 3.132. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.477. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.132TTM3.477-0.345
TTM3.477YOY4.863-1.386
TTM3.4775Y10.880-7.403
5Y10.88010Y11.382-0.502
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1323.987-0.855
TTM3.4774.440-0.963
YOY4.8635.569-0.706
5Y10.8806.158+4.722
10Y11.3826.492+4.890
1.3.2. Quick Ratio

Measures if Calliditas is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Calliditas to the Biotechnology industry mean.
  • A Quick Ratio of 2.87 means the company can pay off kr2.87 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Calliditas Therapeutics:

  • The MRQ is 2.875. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.308. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.875TTM3.308-0.433
TTM3.308YOY4.655-1.348
TTM3.3085Y7.286-3.978
5Y7.28610Y6.939+0.347
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8753.653-0.778
TTM3.3084.158-0.850
YOY4.6555.515-0.860
5Y7.2866.012+1.274
10Y6.9396.206+0.733

1.4. Solvency of Calliditas Therapeutics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Calliditas assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Calliditas to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.82 means that Calliditas assets are financed with 82.0% credit (debt) and the remaining percentage (100% - 82.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Calliditas Therapeutics:

  • The MRQ is 0.820. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.744. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.820TTM0.744+0.076
TTM0.744YOY0.497+0.247
TTM0.7445Y0.325+0.419
5Y0.32510Y0.312+0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8200.336+0.484
TTM0.7440.330+0.414
YOY0.4970.267+0.230
5Y0.3250.367-0.042
10Y0.3120.378-0.066
1.4.2. Debt to Equity Ratio

Measures if Calliditas is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Calliditas to the Biotechnology industry mean.
  • A Debt to Equity ratio of 455.3% means that company has kr4.55 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Calliditas Therapeutics:

  • The MRQ is 4.553. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.138. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.553TTM3.138+1.416
TTM3.138YOY1.051+2.086
TTM3.1385Y0.936+2.201
5Y0.93610Y0.894+0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5530.376+4.177
TTM3.1380.398+2.740
YOY1.0510.334+0.717
5Y0.9360.431+0.505
10Y0.8940.476+0.418

2. Market Valuation of Calliditas Therapeutics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Calliditas generates.

  • Above 15 is considered overpriced but always compare Calliditas to the Biotechnology industry mean.
  • A PE ratio of -92.85 means the investor is paying kr-92.85 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Calliditas Therapeutics:

  • The EOD is -82.840. Based on the earnings, the company is expensive. -2
  • The MRQ is -92.848. Based on the earnings, the company is expensive. -2
  • The TTM is -30.560. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-82.840MRQ-92.848+10.008
MRQ-92.848TTM-30.560-62.288
TTM-30.560YOY-118.500+87.940
TTM-30.5605Y-31.686+1.126
5Y-31.68610Y-30.813-0.873
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-82.840-2.697-80.143
MRQ-92.848-2.422-90.426
TTM-30.560-2.709-27.851
YOY-118.500-4.116-114.384
5Y-31.686-6.257-25.429
10Y-30.813-6.478-24.335
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Calliditas Therapeutics:

  • The EOD is 66.606. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 74.652. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 9.836. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD66.606MRQ74.652-8.047
MRQ74.652TTM9.836+64.816
TTM9.836YOY-3.864+13.700
TTM9.8365Y-9.610+19.446
5Y-9.61010Y-9.814+0.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD66.606-3.344+69.950
MRQ74.652-2.939+77.591
TTM9.836-3.486+13.322
YOY-3.864-5.592+1.728
5Y-9.610-8.464-1.146
10Y-9.814-8.872-0.942
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Calliditas is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 20.38 means the investor is paying kr20.38 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Calliditas Therapeutics:

  • The EOD is 18.179. Based on the equity, the company is expensive. -2
  • The MRQ is 20.375. Based on the equity, the company is expensive. -2
  • The TTM is 13.965. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD18.179MRQ20.375-2.196
MRQ20.375TTM13.965+6.410
TTM13.965YOY6.286+7.679
TTM13.9655Y7.135+6.830
5Y7.13510Y6.977+0.158
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD18.1792.198+15.981
MRQ20.3752.042+18.333
TTM13.9652.121+11.844
YOY6.2862.907+3.379
5Y7.1353.682+3.453
10Y6.9774.114+2.863
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Calliditas Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.328-2.010+512%-1.127+243%-0.264-20%0.297-211%
Book Value Per Share--6.2388.296-25%14.367-57%15.701-60%15.502-60%
Current Ratio--3.1323.477-10%4.863-36%10.880-71%11.382-72%
Debt To Asset Ratio--0.8200.744+10%0.497+65%0.325+152%0.312+163%
Debt To Equity Ratio--4.5533.138+45%1.051+333%0.936+386%0.894+409%
Dividend Per Share----0%-0%-0%-0%
Eps---0.342-2.171+535%-1.920+461%-1.712+400%-1.670+388%
Free Cash Flow Per Share--0.426-2.025+576%-1.462+443%-1.532+460%-1.497+452%
Free Cash Flow To Equity Per Share--4.311-1.095+125%1.221+253%0.684+531%0.615+601%
Gross Profit Margin--1.0001.997-50%17.480-94%4.495-78%4.329-77%
Intrinsic Value_10Y_max--83.384--------
Intrinsic Value_10Y_min--66.408--------
Intrinsic Value_1Y_max---5.346--------
Intrinsic Value_1Y_min---5.259--------
Intrinsic Value_3Y_max---5.620--------
Intrinsic Value_3Y_min---5.576--------
Intrinsic Value_5Y_max--6.695--------
Intrinsic Value_5Y_min--5.315--------
Market Cap6086416140.000-12%6821723910.0005858309715.000+16%4821096382.500+41%5193191633.775+31%5058352622.643+35%
Net Profit Margin---0.041-0.483+1088%-1.803+4332%-28.822+70756%-81.447+200130%
Operating Margin----0.4380%-1.9090%-24.7360%-78.2400%
Operating Ratio--0.9351.429-35%2.882-68%26.117-96%79.555-99%
Pb Ratio18.179-12%20.37513.965+46%6.286+224%7.135+186%6.977+192%
Pe Ratio-82.840+11%-92.848-30.560-67%-118.500+28%-31.686-66%-30.813-67%
Price Per Share113.400-12%127.100109.150+16%89.825+41%96.758+31%94.245+35%
Price To Free Cash Flow Ratio66.606-12%74.6529.836+659%-3.864+105%-9.610+113%-9.814+113%
Price To Total Gains Ratio-345.250+11%-386.960-128.538-67%248.435-256%-2.387-99%-2.091-99%
Quick Ratio--2.8753.308-13%4.655-38%7.286-61%6.939-59%
Return On Assets---0.010-0.068+591%-0.073+644%-0.065+558%-0.065+560%
Return On Equity---0.055-0.258+371%-0.130+138%-0.123+124%-0.120+119%
Total Gains Per Share---0.328-2.010+512%-1.127+243%-0.264-20%0.297-211%
Usd Book Value--31471764.00041853758.500-25%72484246.000-57%79213057.400-60%78208076.095-60%
Usd Book Value Change Per Share---0.031-0.189+512%-0.106+243%-0.025-20%0.028-211%
Usd Book Value Per Share--0.5860.780-25%1.351-57%1.476-60%1.457-60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.032-0.204+535%-0.181+461%-0.161+400%-0.157+388%
Usd Free Cash Flow--2147430.000-10214392.500+576%-7375827.500+443%-7729084.200+460%-7551208.000+452%
Usd Free Cash Flow Per Share--0.040-0.190+576%-0.137+443%-0.144+460%-0.141+452%
Usd Free Cash Flow To Equity Per Share--0.405-0.103+125%0.115+253%0.064+531%0.058+601%
Usd Market Cap572123117.160-12%641242047.540550681113.210+16%453183059.955+41%488160013.575+31%475485146.528+35%
Usd Price Per Share10.660-12%11.94710.260+16%8.444+41%9.095+31%8.859+35%
Usd Profit---1726592.000-10955324.000+535%-9688274.500+461%-8628194.200+400%-8415282.857+387%
Usd Revenue--42446734.00028361891.500+50%18867656.500+125%11396644.600+272%10854121.810+291%
Usd Total Gains Per Share---0.031-0.189+512%-0.106+243%-0.025-20%0.028-211%
 EOD+4 -4MRQTTM+21 -12YOY+20 -135Y+17 -1610Y+17 -16

3.2. Fundamental Score

Let's check the fundamental score of Calliditas Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-82.840
Price to Book Ratio (EOD)Between0-118.179
Net Profit Margin (MRQ)Greater than0-0.041
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.875
Current Ratio (MRQ)Greater than13.132
Debt to Asset Ratio (MRQ)Less than10.820
Debt to Equity Ratio (MRQ)Less than14.553
Return on Equity (MRQ)Greater than0.15-0.055
Return on Assets (MRQ)Greater than0.05-0.010
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Calliditas Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.713
Ma 20Greater thanMa 50113.390
Ma 50Greater thanMa 100112.796
Ma 100Greater thanMa 200109.865
OpenGreater thanClose114.800
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Operating Income  -12,362-171,739-184,101108,929-75,172-84,401-159,573188,99229,419



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets1,859,245
Total Liabilities1,524,439
Total Stockholder Equity334,806
 As reported
Total Liabilities 1,524,439
Total Stockholder Equity+ 334,806
Total Assets = 1,859,245

Assets

Total Assets1,859,245
Total Current Assets1,275,152
Long-term Assets584,093
Total Current Assets
Cash And Cash Equivalents 973,733
Net Receivables 196,666
Inventory 20,428
Other Current Assets 84,325
Total Current Assets  (as reported)1,275,152
Total Current Assets  (calculated)1,275,152
+/-0
Long-term Assets
Property Plant Equipment 54,239
Long-term Assets Other 479,338
Long-term Assets  (as reported)584,093
Long-term Assets  (calculated)533,577
+/- 50,516

Liabilities & Shareholders' Equity

Total Current Liabilities407,144
Long-term Liabilities1,117,295
Total Stockholder Equity334,806
Total Current Liabilities
Accounts payable 100,564
Other Current Liabilities 306,580
Total Current Liabilities  (as reported)407,144
Total Current Liabilities  (calculated)407,144
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)1,117,295
Long-term Liabilities  (calculated)0
+/- 1,117,295
Total Stockholder Equity
Common Stock2,383
Other Stockholders Equity 332,423
Total Stockholder Equity (as reported)334,806
Total Stockholder Equity (calculated)334,806
+/-0
Other
Cash and Short Term Investments 973,733
Common Stock Shares Outstanding 53,672
Liabilities and Stockholders Equity 1,859,245
Net Debt -7,137
Net Working Capital 868,008
Short Long Term Debt Total 966,596



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
648,417
605,197
706,476
840,846
845,200
784,246
1,486,912
1,440,183
1,506,450
1,386,726
1,231,555
1,768,664
1,459,910
1,344,340
1,458,293
1,518,106
1,952,973
1,788,716
1,709,147
1,611,891
1,859,245
1,859,2451,611,8911,709,1471,788,7161,952,9731,518,1061,458,2931,344,3401,459,9101,768,6641,231,5551,386,7261,506,4501,440,1831,486,912784,246845,200840,846706,476605,197648,417
   > Total Current Assets 
647,969
604,465
696,393
816,435
821,132
760,724
1,463,836
1,417,773
1,036,851
907,867
736,582
1,256,159
1,012,772
896,478
950,142
973,099
1,412,204
1,219,706
1,113,587
1,036,012
1,275,152
1,275,1521,036,0121,113,5871,219,7061,412,204973,099950,142896,4781,012,7721,256,159736,582907,8671,036,8511,417,7731,463,836760,724821,132816,435696,393604,465647,969
       Cash And Cash Equivalents 
646,175
596,850
534,863
805,075
753,540
728,574
1,459,569
1,396,869
996,304
867,346
709,306
1,163,818
955,507
825,409
846,799
736,161
1,249,094
1,013,600
866,181
786,883
973,733
973,733786,883866,1811,013,6001,249,094736,161846,799825,409955,5071,163,818709,306867,346996,3041,396,8691,459,569728,574753,540805,075534,863596,850646,175
       Net Receivables 
0
0
0
0
46,586
0
0
0
0
0
0
55,474
11,343
19,293
52,873
187,179
159,462
109,551
229,708
233,125
196,666
196,666233,125229,708109,551159,462187,17952,87319,29311,34355,47400000046,5860000
       Other Current Assets 
1,630
7,615
161,530
11,360
2,719
32,150
4,267
20,904
22,801
40,521
27,276
0
45,033
-1
1
2
1
84,395
1
-1
84,325
84,325-1184,395121-145,033027,27640,52122,80120,9044,26732,1502,71911,360161,5307,6151,630
   > Long-term Assets 
0
732
10,083
24,411
24,068
23,522
23,076
22,410
469,599
478,859
494,973
512,505
447,138
447,862
508,151
545,007
540,770
569,010
595,560
575,879
584,093
584,093575,879595,560569,010540,770545,007508,151447,862447,138512,505494,973478,859469,59922,41023,07623,52224,06824,41110,0837320
       Property Plant Equipment 
107
391
7,413
6,697
6,063
5,517
4,875
4,233
5,407
5,879
8,837
21,276
39,609
37,513
36,620
35,861
31,920
42,559
41,493
55,513
54,239
54,23955,51341,49342,55931,92035,86136,62037,51339,60921,2768,8375,8795,4074,2334,8755,5176,0636,6977,413391107
       Goodwill 
0
0
0
0
0
0
0
0
47,252
0
0
48,022
37,227
37,400
43,400
46,100
45,800
0
0
0
0
000045,80046,10043,40037,40037,22748,0220047,25200000000
       Long Term Investments 
1
341
2,670
1,939
1,939
1,939
2,135
2,111
2,225
2,230
3,942
3,944
3,915
5,842
5,807
6,909
11,210
0
16,617
20,865
0
020,86516,617011,2106,9095,8075,8423,9153,9443,9422,2302,2252,1112,1351,9391,9391,9392,6703411
       Intangible Assets 
0
0
0
15,775
16,066
16,066
16,066
16,066
414,115
470,244
481,310
484,686
362,191
363,552
416,904
441,248
438,041
485,091
515,028
476,511
0
0476,511515,028485,091438,041441,248416,904363,552362,191484,686481,310470,244414,11516,06616,06616,06616,06615,775000
       Long-term Assets Other 
0
732
10,083
24,411
24,068
23,522
0
0
0
0
-1
-1
1,686
-2
0
0
6,852
0
-1
0
479,338
479,3380-106,85200-21,686-1-1000023,52224,06824,41110,0837320
> Total Liabilities 
30,242
29,589
47,453
30,879
57,129
59,732
61,796
63,395
250,150
254,551
260,853
506,815
451,628
473,197
737,199
792,170
1,186,710
1,199,313
1,204,780
1,259,456
1,524,439
1,524,4391,259,4561,204,7801,199,3131,186,710792,170737,199473,197451,628506,815260,853254,551250,15063,39561,79659,73257,12930,87947,45329,58930,242
   > Total Current Liabilities 
30,242
29,589
42,577
26,624
53,370
57,144
59,522
60,430
105,619
117,211
122,060
140,072
135,446
167,075
178,494
220,120
325,231
310,080
290,309
344,711
407,144
407,144344,711290,309310,080325,231220,120178,494167,075135,446140,072122,060117,211105,61960,43059,52257,14453,37026,62442,57729,58930,242
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,374
0
0
0
0
000010,3740000000000000000
       Accounts payable 
22,643
20,803
32,481
14,941
24,384
28,363
29,520
19,872
53,827
57,660
59,263
74,855
67,971
100,051
81,666
95,763
160,404
108,000
72,037
67,165
100,564
100,56467,16572,037108,000160,40495,76381,666100,05167,97174,85559,26357,66053,82719,87229,52028,36324,38414,94132,48120,80322,643
       Other Current Liabilities 
904
2,730
3,313
3,285
1,859
3,818
5,161
3,922
6,498
6,712
8,991
10,643
62,867
67,024
96,828
124,357
164,827
202,080
218,272
277,546
306,580
306,580277,546218,272202,080164,827124,35796,82867,02462,86710,6438,9916,7126,4983,9225,1613,8181,8593,2853,3132,730904
   > Long-term Liabilities 
0
0
4,876
4,255
3,759
2,588
2,274
2,965
144,531
137,340
138,793
338,066
316,182
306,122
558,705
572,050
861,479
889,233
914,471
914,745
1,117,295
1,117,295914,745914,471889,233861,479572,050558,705306,122316,182338,066138,793137,340144,5312,9652,2742,5883,7594,2554,87600
       Long term Debt Total 
0
0
0
0
0
0
0
0
878
1,319
60,945
187,427
213,216
214,491
458,027
467,317
728,822
746,898
779,564
770,161
0
0770,161779,564746,898728,822467,317458,027214,491213,216187,42760,9451,31987800000000
       Other Liabilities 
0
0
11
45
175
250
603
1,931
143,653
136,021
135,315
136,198
102,967
91,632
100,678
104,733
132,656
142,335
0
144,584
0
0144,5840142,335132,656104,733100,67891,632102,967136,198135,315136,021143,6531,931603250175451100
> Total Stockholder Equity
618,175
575,608
659,023
809,967
788,071
724,514
1,425,116
1,376,788
1,210,491
1,095,341
937,842
1,261,849
1,008,282
871,143
721,094
725,936
766,263
589,403
504,367
352,435
334,806
334,806352,435504,367589,403766,263725,936721,094871,1431,008,2821,261,849937,8421,095,3411,210,4911,376,7881,425,116724,514788,071809,967659,023575,608618,175
   Common Stock
1,408
1,408
1,408
1,548
1,548
1,548
1,918
1,998
1,998
1,998
1,998
2,094
2,094
2,094
2,364
2,366
2,383
2,383
2,383
2,383
2,383
2,3832,3832,3832,3832,3832,3662,3642,0942,0942,0941,9981,9981,9981,9981,9181,5481,5481,5481,4081,4081,408
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
-26,979
0
0
0
9,307
0
0
0
0
00009,307000-26,979000000000000
   Capital Surplus 
0
0
0
0
1,274,664
1,274,771
2,036,378
2,126,016
2,133,179
2,135,476
2,141,445
2,451,979
2,459,741
2,529,556
2,539,458
2,548,946
2,590,890
0
0
0
0
00002,590,8902,548,9462,539,4582,529,5562,459,7412,451,9792,141,4452,135,4762,133,1792,126,0162,036,3781,274,7711,274,6640000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
-34
0
0
0
-45
0
2
-20
-6,090
0
0
0
2,459,741
2,529,556
2,539,458
2,548,946
2,581,583
587,020
501,984
350,052
332,423
332,423350,052501,984587,0202,581,5832,548,9462,539,4582,529,5562,459,741000-6,090-2020-45000-34



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,206,888
Cost of Revenue-60,463
Gross Profit1,146,4251,146,425
 
Operating Income (+$)
Gross Profit1,146,425
Operating Expense-1,562,954
Operating Income-416,529-416,529
 
Operating Expense (+$)
Research Development502,223
Selling General Administrative319,395
Selling And Marketing Expenses721,084
Operating Expense1,562,9541,542,702
 
Net Interest Income (+$)
Interest Income0
Interest Expense-83,962
Other Finance Cost-13,050
Net Interest Income-97,012
 
Pretax Income (+$)
Operating Income-416,529
Net Interest Income-97,012
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-457,017-376,041
EBIT - interestExpense = -466,286
-457,017
-382,223
Interest Expense83,962
Earnings Before Interest and Taxes (EBIT)-382,324-373,055
Earnings Before Interest and Taxes (EBITDA)-416,529
 
After tax Income (+$)
Income Before Tax-457,017
Tax Provision-18,803
Net Income From Continuing Ops-451,497-475,820
Net Income-466,185
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,623,417
Total Other Income/Expenses Net-40,48897,012
 

Technical Analysis of Calliditas
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Calliditas. The general trend of Calliditas is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Calliditas's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Calliditas Therapeutics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 121.70 < 136.00 < 141.90.

The bearish price targets are: 109.00 > 107.10 > 105.80.

Tweet this
Calliditas Therapeutics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Calliditas Therapeutics. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Calliditas Therapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Calliditas Therapeutics. The current macd is 0.46430546.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Calliditas price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Calliditas. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Calliditas price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Calliditas Therapeutics Daily Moving Average Convergence/Divergence (MACD) ChartCalliditas Therapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Calliditas Therapeutics. The current adx is 11.98.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Calliditas shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Calliditas Therapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Calliditas Therapeutics. The current sar is 108.64.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Calliditas Therapeutics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Calliditas Therapeutics. The current rsi is 50.71. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Calliditas Therapeutics Daily Relative Strength Index (RSI) ChartCalliditas Therapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Calliditas Therapeutics. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 3/(-6 +6).

  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Calliditas price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Calliditas Therapeutics Daily Stochastic Oscillator ChartCalliditas Therapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Calliditas Therapeutics. The current cci is 15.62.

Calliditas Therapeutics Daily Commodity Channel Index (CCI) ChartCalliditas Therapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Calliditas Therapeutics. The current cmo is 0.75832953.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Calliditas Therapeutics Daily Chande Momentum Oscillator (CMO) ChartCalliditas Therapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Calliditas Therapeutics. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Calliditas is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Calliditas Therapeutics Daily Williams %R ChartCalliditas Therapeutics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Calliditas Therapeutics.

Calliditas Therapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Calliditas Therapeutics. The current atr is 4.01345541.

Calliditas Therapeutics Daily Average True Range (ATR) ChartCalliditas Therapeutics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Calliditas Therapeutics. The current obv is 2,861,642.

Calliditas Therapeutics Daily On-Balance Volume (OBV) ChartCalliditas Therapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Calliditas Therapeutics. The current mfi is 48.92.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Calliditas Therapeutics Daily Money Flow Index (MFI) ChartCalliditas Therapeutics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Calliditas Therapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Calliditas Therapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Calliditas Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.713
Ma 20Greater thanMa 50113.390
Ma 50Greater thanMa 100112.796
Ma 100Greater thanMa 200109.865
OpenGreater thanClose114.800
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Calliditas with someone you think should read this too:
  • Are you bullish or bearish on Calliditas? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Calliditas? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Calliditas Therapeutics

I send you an email if I find something interesting about Calliditas Therapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about Calliditas Therapeutics.

Receive notifications about Calliditas Therapeutics in your mailbox!